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studies are available that allow comparison of the in vitro 
translocation to in vivo data. This situation could change 
since the availability of analytical detection techniques is 
no longer a limiting factor for this comparison. We con-
clude that to further develop in vitro models to be used in 
risk assessment, the current strategy to improve the models 
to more closely mimic the human situation by using co-
cultures of different cell types and microfluidic approaches 
to better control the tissue microenvironments are essential. 
At the current state of the art, the in vitro models do not 
yet allow prediction of absolute transfer rates but they do 
support the definition of relative transfer rates and can thus 
help to reduce animal testing by setting priorities for subse-
quent in vivo testing.
Keywords In vitro models · Nanoparticles · 
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General introduction
Nanoparticles have attractive and novel properties com-
pared with their bulk counterparts and are therefore used in 
an increasing number of consumer products (Nanotechnol-
ogies 2014). Examples are zinc oxide and titanium diox-
ide nanoparticles in sunscreens and silver nanoparticles in 
food packaging material, textiles, and cosmetics, but many 
more have been identified (Bouwmeester et al. 2014). The 
increasing use of nanoparticles in products likely results 
in increasing exposure of both workers and consumers. 
Because of the unique properties of nanoparticles that are 
related to their small size, concerns arise that nanoparticles 
would unintentionally cross the barriers of the human body, 
which would result in internal exposure to nanoparticles 
potentially leading to adverse effects.
Abstract The increasing use of nanoparticles in products 
likely results in increased exposure of both workers and 
consumers. Because of their small size, there are concerns 
that nanoparticles unintentionally cross the barriers of the 
human body. Several in vivo rodent studies show that, 
dependent on the exposure route, time, and concentration, 
and their characteristics, nanoparticles can cross the lung, 
gut, skin, and placental barrier. This review aims to evalu-
ate the performance of in vitro models that mimic the bar-
riers of the human body, with a focus on the lung, gut, skin, 
and placental barrier. For these barriers, in vitro models 
of varying complexity are available, ranging from single-
cell-type monolayer to multi-cell (3D) models. Only a few 
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Several in vivo studies have been performed to assess 
the distribution of nanoparticles after inhalation, oral expo-
sure, skin exposure, and intravenous injection (Balasubra-
manian et al. 2010; Braakhuis et al. 2014a; Creutzenberg 
et al. 2012; De Jong et al. 2008; Elder et al. 2006; Geraets 
et al. 2012; Kreyling et al. 2009; Leite-Silva et al. 2013; 
Ma-Hock et al. 2012; Oberdorster et al. 2004; Semmler 
et al. 2004; Takenaka et al. 2001; van der Zande et al. 2012, 
2014). These studies show that, depending on the exposure 
route, time, concentration, as well as on their characteris-
tics, nanoparticles can cross the lung, gut, skin, and placen-
tal barrier.
Information on the kinetics of nanoparticles in the 
human body is essential for risk assessment purposes, 
because of their potency to accumulate. The overall result-
ant of absorption, distribution, metabolism, and excretion 
(ADME), i.e. internal exposure, will determine target tissue 
doses and will be critical for the ultimate systemic adverse 
health effects (Geraets et al. 2014). Even in cases of low 
absorption of nanoparticles, the often chronic nature of the 
exposure (inhalatory, oral or dermal) might result in inter-
nal accumulation of the nanoparticles potentially reaching 
levels that might give rise to health concerns (van Kesteren 
et al. 2014). The current risk assessment of nanoparticles 
(and chemicals) mainly relies on in vivo studies using 
animal models (EFSA 2011). While these in vivo studies 
provide unique information on the distribution of nanopar-
ticles in a whole organism, the number of animal studies 
should be reduced as much as possible for several reasons 
(Hartung et al. 2013). First, the use of animals is ethically 
debatable. Secondly, animal models do not fully simulate 
the physiology of humans. Lastly, given the great number 
of and variety in different nanoparticles, it is impossible 
and economically not feasible to test all of them through 
in vivo studies. Therefore, in vitro models have been devel-
oped to study the translocation of nanoparticles (Hartung 
et al. 2013) and estimate the in vivo internal exposure. 
However, before such in vitro models can reliably be used 
in risk assessment of nanoparticles, they need to be well 
described and validated (Kandarova and Letasiova 2011; 
Worth and Balls 2004) using in vivo data (Genschow et al. 
2002).
To obtain reliable NP kinetic data from in vitro or in 
vivo studies, robust analytical detection methods should 
be used in the experiments. Over the last couple of years, 
the quality of NP characterization methods used in kinetic 
studies has been improved, but much is to be gained here. 
Therefore, we reviewed the current state of the knowledge 
on analytical detection methods and proposed directions 
for further improvement and incorporation in in vitro or in 
vivo studies.
In this review we aimed to evaluate the existence and 
performance of in vitro models that mimic the barriers of 
the human body. Where possible we compare the observed 
translocation in vitro to the in vivo translocation to compare 
to what extent the in vitro results mimic the in vivo situa-
tion. In addition, we have included the placental barrier that 
protects the unborn foetus from exposure via the maternal 
circulation. For an overview on the status of alternatives 
for regulatory toxicology in general, we refer to the 2014 
JRC Science and Policy Report by Worth et al. (2014). We 
first describe the different in vitro models that are currently 
in use to study the transfer of nanoparticles via inhalation, 
oral uptake, skin uptake, and placental uptake. In vitro 
models that are used only to assess the toxicity of nanopar-
ticles, but not to measure translocation, are excluded from 
this review. After defining the in vitro models available to 
study transfer across the different barriers, we compare the 
results of the in vitro models with available in vivo data 
and discuss their predictive value. Finally, we give recom-
mendations for the future development of relevant in vitro 
models.
Introduction to the lung barrier
The main function of the lungs is to transport oxygen from 
the atmosphere into the bloodstream and to release carbon 
dioxide from the bloodstream into the atmosphere. During 
inhalation, air travels from the mouth or nose through the 
nasopharynx, oropharynx, larynx, and trachea. The trachea 
divides into two main bronchi, which branch to the left 
and right lungs and subsequently subdivide into a system 
of bronchi and bronchioles until the alveoli where the gas 
exchange takes place. The airways are lined by ciliated res-
piratory epithelium, which is covered by a mucus layer. The 
mucociliary movement is an important clearance mecha-
nism, especially to remove inhaled (nano)particles. Deeper 
in the airways, the clearance is slower, given the increased 
pathway length and decreased mucous velocity (Geiser and 
Kreyling 2010). Nanoparticles, especially those that dis-
solve readily such as ZnO, may be able to translocate the 
mucus layer and reach the epithelial cells and thus cause 
local damage (Frieke Kuper et al. 2015; Landsiedel et al. 
2014a; Vandebriel and De Jong 2012). They may also be 
able to cross the epithelial barrier and reach underlying 
interstitium with its blood and lymph vasculature.
The alveoli are lined by a single epithelial layer under 
which is an interstitium with extracellular matrix, blood 
capillaries, and stromal cells. The epithelial layer is cov-
ered by surfactant at the alveolar luminal side. Alveolar 
type I cells form the structure of the alveolar wall. These 
cells are very thin to improve the gas exchange. In addi-
tion, type I cells have tight junctions to prevent chemicals 
and particles from entering the bloodstream. Besides type I 
cells, alveolar type II cells secrete pulmonary surfactant to 
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lower the surface tension. Finally, for clearance of particles 
and pathogens from the lungs, alveolar macrophages are 
present (Klein et al. 2011; Möller et al. 2010).
To cross the lung–blood barrier, nanoparticles must 
deposit in the alveolar region. The deposition of inhaled 
particles depends on the morphology of the lungs, the 
respiratory conditions, and the physicochemical proper-
ties of the particles. The most important physicochemical 
properties of inhaled particles that influence deposition are 
(agglomerate) size, size distribution, density, shape, charge, 
and hygroscopicity (Braakhuis et al. 2014b; Carvalho et al. 
2011; Pilcer and Amighi 2010). When the agglomerate size 
of nanoparticles is <100 nm but >10 nm, a considerable 
part will deposit in the alveolar region (about 30 % of the 
particles) (Asgharian et al. 2009; ICRP 1994; Oberdorster 
1989). Below 30 nm, the deposition shifts from the alveoli 
more towards to tracheobronchial region (Braakhuis et al. 
2014b).
Once deposited in the alveoli, nanoparticles can be 
cleared from the lungs by alveolar macrophages. How-
ever, single nanoparticles and agglomerates of <100 nm 
are less efficiently phagocytized by alveolar macrophages 
compared with microparticles or large agglomerates of 
>1 µm (Bakand et al. 2012; Muhlfeld et al. 2008; Phalen 
et al. 2010). After uptake of the particles, macrophages 
can move gradually upward by the mucociliary escalator, 
are subsequently swallowed, and enter the gastrointestinal 
tract. If not cleared by phagocytosis, nanoparticles can be 
taken up by the alveolar epithelium and reach the pulmo-
nary interstitium from which they are transported to the 
local lymph nodes, or reach the blood circulation (Borm 
et al. 2006). Translocated particles may subsequently reach 
organs where they can be taken up and might cause damage 
(Braakhuis et al. 2014b).
Introduction to the intestinal barrier
The primary functions of the human gastrointestinal (GI) 
tract are related to the digestion and absorption of nutrients 
and electrolytes, and to water homeostasis. The GI tract is 
responsive to internal stimuli as well as to (microbe) stim-
uli from the lumen content. The GI epithelial layer forms 
a tight, but selective barrier: nutrients are absorbed effi-
ciently, while microbes, for example, are not. Anatomically 
the gut wall can be divided into the mucosa, submucosa, 
muscularis externa, and serosa. At the lumen site, the gut 
wall consists of a mucosa, which is a combined mucus and 
cell epithelial layer. The composition of the mucus and 
the type of cells is variable along the GI tract and reflects 
the specialized function of each region. The submucosa 
is a layer of connective tissue that contains lymphatic and 
blood vessels as well as ganglion and nerve cells. In the 
next layer, the muscularis externa, the main smooth mus-
cles of the gut are found. The thickness of the muscle layer 
varies. The serosa is a squamous epithelium (mesothelium) 
which sits on connective tissue and is continuous with the 
abdominal peritoneum.
The small intestine is the site where most of the chemi-
cal and mechanical digestion takes place and where almost 
all of the absorption of nutrients and electrolytes is carried 
out. The wall of the small intestine is lined with absorp-
tive mucosa. The mucosal surface is extended by the pres-
ence of crypts and villi. The most common epithelial cell is 
the enterocyte, its major function being to absorb nutrients. 
The second cell type is the mucus-secreting goblet cell, the 
mucus acts as a lubricant and protects the mucosa from irri-
tation. Lastly, the gut-associated lymphoid tissue (GALT) 
includes several specialized cells including Peyer’s patches, 
M cells, and intraepithelial lymphocytes, which are part of 
the intestinal immune system.
Following ingestion, translocation of particles into and 
across the gastrointestinal mucosa can occur via four differ-
ent: (1) via endocytosis, through enterocytes, (2) via the M 
cell-rich layer of Peyer’s patches (small intestinal lymphoid 
aggregates), (3) via persorption, where particles can trans-
locate through a ‘hole’ left in the epithelium when entero-
cytes shed from the villous tip, and (4) via the paracellular 
route, where nanoparticles pass across tight junctions of the 
epithelial cell layer (Powell et al. 2010). While the expo-
sure of the gastrointestinal mucosa to engineered nanopar-
ticles might pose yet unresolved heath issues, it is impor-
tant to realize that people in the Western world are daily 
exposed to sub-micrometre-sized mineral particles (Powell 
et al. 1996, 2010). These particles have been observed to 
be composed of aluminosilicates, titanium dioxide, and a 
small percentage of non-aluminium-containing silicates 
such as silica (Si02) and magnesium trisilicate (talc) (Dek-
kers et al. 2011; Powell et al. 1996).
Introduction to the skin barrier
The skin is a barrier towards loss of water and ingress of 
microorganisms, UV radiation, and potentially harmful 
chemicals. Although the permeability of skin is an order 
of magnitude less than that of the intestinal epithelial cell 
layer, due to its large surface of almost 2 m2 and likeli-
hood of dermal exposure in everyday life, the skin can 
pose an important absorption route for nanoparticles. The 
barrier function of the skin is generally attributed to its 
upper layer, the stratum corneum. The stratum corneum 
consists of stacked layers of corneocytes, enucleated flat-
tened cells that are surrounded by impermeable cornified 
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envelope and embedded in organized lipid bilayers. There 
are three potential routes by which a penetrant can diffuse 
across the stratum corneum: (1) across the lipid bilayers 
(intercellular route; Fig. 1a), (2) across the corneocytes 
and lipid bilayers (intracellular route; Fig. 1b), and (3) 
along hair follicles and sweat glands (Fig. 1c). The intra-
cellular route is thermodynamically unfavourable due to 
the highly impermeable cornified envelope of the corneo-
cytes. For most chemicals, the route across lipid bilay-
ers represents the main diffusional pathway. The stratum 
corneum lipids are organized in two coexisting lamellar 
phases: a long periodicity phase with a repeat distance 
of around 13 nm and a short periodicity phase with a 
repeat distance of around 6 nm (Baroli 2010). The space 
between the tail–tail and head–head domains of the lipid 
bilayers (Fig. 1) restricts the size of a NP that is able to 
penetrate across the stratum corneum (Baroli 2010; Cevc 
and Vierl 2010). Another restriction factor for the pen-
etration of nanoparticles across the intracellular route is 
high diffusion resistance for particles larger than 5 nm 
(Watkinson et al. 2013). Thus, theoretically for nanopar-
ticles larger than approximately 5 nm the route along hair 
follicles might represent the predominant penetration 
route.
This view, however, can be challenged in the case of a 
compromised skin barrier, which can occur due to intrin-
sic and environmental factors. For instance, one of the main 
features of a common inflammatory skin disease, atopic 
dermatitis (AD), is a damaged skin barrier (Kezic et al. 
2014). Furthermore, exposure to skin irritating chemicals 
such as detergents and organic solvents in the work place as 
well as in everyday life can also lead to increased skin per-
meability (Kezic and Nielsen 2009). Data on percutaneous 
penetration of nanoparticles are scarce. Recently, Labouta 
et al. 2011a, b showed that in contrast to intact skin barrier, 
the skin compromised by toluene allows for penetration 
of nanoparticles of 15 nm into viable skin (Labouta et al. 
2011b).
Fig. 1  A Schematic illustration 
of the skin and main penetration 
routes, insert showing the lipid 
bilayers between corneocytes. 
Route A: across the lipid bilay-
ers (intercellular route); Route 
B: across the corneocytes and 
lipid bilayers (intracellular 
route); Route C: along hair fol-
licles and sweat glands
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Introduction to the placental barrier
The human placenta is a unique organ, structurally com-
plex, highly efficient, and metabolically and biosyntheti-
cally active (Aye and Keelan 2013). The placenta is respon-
sible for the (bidirectional) transfer of substances between 
the maternal and foetal circulations including carbon diox-
ide, oxygen, water, nutrients, hormones, vitamins, and also 
xenobiotics including drugs and toxic compounds (Des-
forges and Sibley 2010). In early pregnancy, the human 
placenta is primarily composed of cytotrophoblasts, which 
continually fuse to form multinucleate syncytiotrophoblasts 
as pregnancy progresses. The syncytiotrophoblast consists 
of two polarized plasma membranes: a maternal-facing 
microvillous plasma membrane (MVM) and a basal plasma 
membrane (BM) oriented towards the foetal circulation 
(Kulvietis et al. 2011; Lager and Powell 2012) (Fig. 2).
The rate-limiting barrier in the human placenta for the 
permeation of substances between maternal blood and 
foetal capillaries is the syncytiotrophoblast (Young et al. 
2003). Once in the cytoplasm of the syncytiotrophoblast, 
molecules destined for the foetus exit from the syncytio-
trophoblast via the foetal facing basal plasma membrane 
(BM) (Desforges and Sibley 2010). At term, the placen-
tal diameter varies between 200 and 220 mm (Benirschke 
et al. 2006). The diffusion distance between the maternal 
and foetal circulations varies between 4 and 5 µm, while 
in the first trimester the distance varies between 50 and 
100 µm (Aye and Keelan 2013; Benirschke et al. 2006). 
Passage across the placenta can occur via simple diffusion, 
pinocytosis, receptor-mediated uptake, and both active and 
facilitated transport (Aye and Keelan 2013). The syncytio-
trophoblast plasma membranes express numerous trans-
porters which may be regulated by foetal, maternal and 
placental signals (Lager and Powell 2012). The anatomy 
and physiology of the human placenta is different from the 
rodent placenta. The main difference is that in humans the 
syncytiotrophoblasts arise from fusion of cytotrophoblast 
cells and form a syncytium with no lateral cell membranes. 
In rodents, three trophoblast layers are present between 
maternal blood and foetal blood capillaries.
Overview of currently used in vitro models 
to study translocation of nanoparticles
Many different in vitro models have been developed to 
study the translocation of nanoparticles. Most in vitro bar-
rier models culture cells on Transwell inserts, which con-
sist of a permeable membrane separating an apical and a 
basolateral compartment. Cells are seeded and cultured on 
the inserts to form a barrier (upon confluence of the cells) 
between the two compartments. Depending on the cell type 
selected, the Transwell model can be used to study lung, 
gastrointestinal, or placental transfer.
Transwells can be used to quantify both uptake of nan-
oparticles into the cells from the apical compartment and 
efflux from the cells to the basolateral compartment as a 
measure of translocation (Fig. 3). Fluorescent polystyrene 
nanoparticles are the most commonly employed because of 
their easy detection.
Skin in vitro models are not based on Transwell inserts, 
because these cell culturing models lack the principal bar-
rier, the stratum corneum. Therefore, ex vivo skin models 
are mostly used for the in vitro assessment of nanoparti-
cles translocation. Also for the other barriers, especially for 
the placental barrier and to a lesser extent for the lung and 
intestinal barrier, ex vivo models are available to test the 
translocation of nanoparticles.
Table 1 presents an overview of in vitro barrier models 
currently used to study the translocation of nanoparticles 
after inhalation, oral intake, dermal exposure, and across 
the placenta.
Lung in vitro models
The most frequently used lung epithelial cells lines are 
A549, Calu-3, H441, and 16HBE14o-. Of these cell lines, 
Calu-3, H441, and 16HBE14o- form tight junctions, but 
Fig. 2  Schematic illustration of the placental barrier as a cross sec-
tion of a human placental villus. The placental barrier consists of two 
layers: the syncytiotrophoblast and cytotrophoblast, the latter form-
ing a discontinuous layer. The basal plasma membrane (BM) of the 
syncytiotrophoblast is oriented towards the foetal circulation, while 
the maternal-facing microvillous plasma membrane (MVM) faces the 
maternal blood compartment
Fig. 3  Two-compartment cell culture system contains a permeable 
cell culture insert, separating two compartments in a Transwell. Cells 
are seeded and cultured on the inserts to form a barrier between the 
two compartments
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A549 do not (Lehmann et al. 2011; Chowdhury et al. 
2010, Geys et al. 2006, Hermanns et al. 2004, George et al. 
2015). In in vitro translocation studies, primary rat alveolar 
cells have also been frequently used (Fazlollahi et al. 2011; 
Geys et al. 2009; Yacobi et al. 2008).
Besides differences in cell types, in vitro lung bar-
rier models differ in whether they are submerged or cul-
tured at the air–liquid interface. Submerged models have 
the advantage of being technically simple. However, the 
culture medium can alter the properties of the nanoparti-
cles, and subsequently their uptake and effects. Air–liquid 
models mimic more realistically the inhalation exposure; 
therefore, many air–liquid models have been developed 
recently (Blank et al. 2006; Brandenberger et al. 2010; 
Frohlich et al. 2013; Herzog et al. 2013; Holder and Marr 
2013; Lenz et al. 2009, 2013; Raemy et al. 2011; Rothen-
Rutishauser et al. 2009; Savi et al. 2008; Xie et al. 2012). 
Disadvantages are the complexity of the system to maintain 
constant temperature and humidification, and the high costs 
in comparison with submerged models.
In recent years, co-culture models containing more 
than one cell type are used to mimic the lung barrier more 
closely compared with monocultures (Klein et al. 2011). 
Most models use lung epithelial cells as a basis, those 
being either primary cells or immortalized cell lines. To 
obtain co-culture models, different cell types are added 
to the basic model. The first type of co-culture models 
includes, in addition to epithelial cells, endothelial cells to 
mimic the alveolar-capillary barrier (Bermudez et al. 2002; 
Chowdhury et al. 2010; Hermanns et al. 2010; Hermanns 
et al. 2004; Papritz et al. 2010). This type of model can be 
extended by the addition of alveolar macrophages, mast 
cells, and/or type II alveolar cells. The second type of mod-
els does not include endothelial cells, but adds dendritic 
cells and macrophages to the epithelial cell layer (Branden-
berger et al. 2010; Muller et al. 2010; Rothen-Rutishauser 
et al. 2008; Rothen-Rutishauser et al. 2005). This type of 
model can also be completed with type II alveolar cells. 
The third type of models includes, in addition to the epithe-
lial cells, fibroblasts instead of endothelial cells, which can 
be extended by adding dendritic cells.
A limited number of nanoparticles have been studied 
to test translocation across the in vitro lung barrier. These 
include polystyrene nanoparticles, titanium dioxide nano-
particles, quantum dots, cerium dioxide nanoparticles, gold 
nanoparticles, silica nanoparticles, diesel particles, and sin-
gle-walled carbon nanotubes (Table 1). The translocation 
rate of nanoparticles is higher in models with cells that do 
not form tight junctions compared with cells that do (Geys 
et al. 2006; Hermanns et al. 2004; George et al. 2015). 
Probably, the higher translocation rate is a consequence 
of paracellular transport, which will not occur in a healthy 
lung but might occur in a damaged or inflamed lung. The 
pore size of the permeable membrane of the inserts also 
influences the translocation rate of nanoparticles: the larger 
the pore size, the higher the translocation rate (Geys et al. 
2006). Therefore, for each single type of nanoparticles, the 
translocation across the different types of inserts should be 
tested without cells to assess whether the nanoparticles are 
not withheld by the insert itself.
Ex vivo tissues as model for the lung are not addressed 
here. The precision-cut lung slices (PCLS) taken from 
human and rodent lungs have been used to study translo-
cation and toxicity of nanomaterials. The use of PCLS for 
translocation of nanoparticle-mediated drug delivery has 
recently been reviewed by Paranjpe and Muller-Goymann 
(Paranjpe and Muller-Goymann 2014).
Gut in vitro models
Orally ingested nanoparticles are exposed to continuously 
changing conditions while transiting through the gastro-
intestinal tract, which influences their nature and charac-
teristics (Bellmann et al. 2015). In vitro GI models aim to 
mimic the gastrointestinal environment as closely as pos-
sible, to generate physiologically relevant results. These 
models focus either on the aspects of dynamically changing 
GI conditions during digestion by simulation of the transit 
of nanoparticles along the GI tract from the mouth towards 
the large intestine (digestion models), or on mimicking 
translocation and uptake behaviour (in vitro human intesti-
nal epithelium models) (Lefebvre et al. 2014).
Human digestion models can first be simple and static, 
and mimic only gastric or small intestinal conditions, in 
which materials are incubated with simulated gastric fluids, 
simulated small intestinal fluids or buffers at static pH val-
ues (Mwilu et al. 2013; Minekus et al. 2014). More complex 
static models often include most of the relevant GI condi-
tions, i.e. the oral, gastric, small intestinal (and large intesti-
nal conditions) (Oomen et al. 2003; Van de Wiele et al. 2007; 
Versantvoort et al. 2005). Recently, these models have been 
used to assess the fate of 60-nm silver nanoparticles, and 
nanometre-sized silica (synthetic amorphous silica) nano-
particles during digestion (Peters et al. 2012; Walczak et al. 
2013). In contrast to static models, more complex dynamic 
models simulate successive changes in conditions (i.e. pH, 
secretion of digestive fluids) and transit times (Helbig et al. 
2013; Kong and Singh 2010; Minekus et al. 1995; Wickham 
et al. 2009; Zangenberg et al. 2001). Such a dynamic com-
puter controlled model was used to study the behaviour of 
engineered nanoclay materials (Newsome 2014).
Translocation and uptake of nanoparticles can be 
addressed by cellular models that can also be divided in 
relatively simple models or more complex ones (Lefebvre 
et al. 2014). Amongst the variety of cell models that are 
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available in vitro, intestinal Caco-2 cells (human epithelial 
colorectal adenocarcinoma cells) are the most commonly 
used cell type (Miret et al. 2004) in nanoparticle transloca-
tion studies. Caco-2 cells are regarded as model cells for 
enterocytes, the most abundant epithelial cell type in the 
intestine. Several examples can be found in the literature 
where monocultures of Caco-2 cells have been used to 
study the in vitro translocation of nanoparticles, (mainly 
polystyrene, but also silicon, silver, and organic nanoparti-
cles) (Bhattacharjee et al. 2013; des Rieux et al. 2007; des 
Rieux et al. 2005; Mahler et al. 2009; Natoli et al. 2012; 
Nkabinde et al. 2012; Walczak et al. 2014).
A potential drawback of Caco-2 monolayers is the lack 
of a mucus layer (at least in conventional models), which 
can, however, be introduced by co-culturing Caco-2 cells 
with HT29-MTX cells (human colon adenocarcinoma 
mucus-secreting cells) (Behrens et al. 2002; Mahler et al. 
2009; Scaldaferri et al. 2012; Walczak et al. 2014). The 
mucus layer consists of mucin glycoproteins that form 
viscoelastic gels, and it is thinner in the small intestine 
compared with the large intestine. Though this makes the 
small intestine a prominent place for nanoparticle uptake, 
the mucus layer also represents a hindrance allowing selec-
tive passage of materials. The mucus can entrap nanoparti-
cles (and thus reduce their translocation) because it poses 
a physical barrier due to its thickness, density, negative 
charge, and constant renewal (Cone 2009; Crater and Car-
rier 2010; Szentkuti and Lorenz 1995). In addition, mucus 
has a protective function for bio-relevant fluids present 
in the lumen of the gut, and direct exposure of Caco-2 
cells (without a mucus layer) to lumen content stimulants 
reduces the barrier function of Caco-2 cells models (Ingels 
et al. 2002). This is probably due to the lack of mucus layer 
making the Caco-2 cells much more sensitive to direct 
exposure to the low pH and high osmolality of the buffers 
(Westerhout et al. 2014).
To further increase the complex anatomy of the human 
gut epithelium, human intestine microfold (M) cells are 
introduced in epithelial monolayers. While M cells in total 
compose less than 1 per cent of the small intestine epithe-
lial cell layer, they are responsible for the uptake and trans-
location of relatively larger particles (Antunes et al. 2013; 
Bouwmeester et al. 2011; des Rieux et al. 2007; des Rieux 
et al. 2005; Kerneis et al. 1997; Martinez-Argudo et al. 
2007; Walczak et al. 2014). Recently, in vitro digestion 
models have been linked to in vitro gut epithelial models to 
study first the digestion of nanoparticles and next the bio-
availability of the digested particles in the intestines (Walc-
zak et al. 2015) (see Table 1).
Several ex vivo gut models have been developed to 
study the translocation of chemicals. Different approaches 
are used ranging from in situ perfusion (intestinal loop) 
models to models in which part of the gut epithelium is 
excised from animals and maintained in, for example, 
Ussing chambers for a limited period of time. These mod-
els have recently been reviewed by Lefebvre et al. (2014). 
These authors summarize studies in which the transloca-
tion of mainly organic nanoparticles have been evaluated, 
only a limited number of studies used polystyrene or tita-
nium nanoparticles that have also been used in vitro (see 
Table 1).
Skin in vitro models
For the determination of dermal absorption of chemicals, 
several guidelines have been established by prescribing the 
type of skin membrane, species, and experimental proto-
col (OECD 2004). However, specifically for nanoparticles, 
there are no such guidelines and critical evaluation of the 
current models is missing. Skin in vitro models differ in the 
type of the skin membrane (full thickness skin vs. dermat-
omed skin), species (human vs. animal skin), vehicle and 
type of the diffusion cell, which hampers comparison and 
interpretation of the results.
In contrast to the lung, intestinal and placental barrier, 
no Transwells are used for percutaneous penetration stud-
ies. The reported in vitro studies on percutaneous penetra-
tion of nanoparticles have been performed by using either 
a Franz static cell or a flow-through diffusion cells. In both 
systems, the skin membrane is clamped between two cham-
bers, one of which contains a vehicle supplemented with the 
investigated chemical (donor chamber) and the other one a 
receptor fluid from which the penetrated chemical will be 
sampled (Fig. 4) (Jakasa and Kezic 2008). In several stud-
ies, human reconstructed skin models have been applied 
although there were concerns regarding a less well-devel-
oped barrier in these models and the absence of the follicu-
lar penetration route that might play an important role for 
translocation of nanoparticles (Labouta et al. 2011a, b). In 
in vitro assays, usually a cryopreserved skin is used, which 
might, however, lead to changes of the skin barrier and 
shrinkage of the hair follicles (Labouta et al. 2011a).
Although human skin is regarded as a gold standard, 
a large number of studies on percutaneous penetration of 
nanoparticles use different animal models including mice, 
rat, and pig skin (Labouta and Schneider 2013). However, 
structural and morphological differences between human 
and animal skin, especially concerning the density of the 
hair follicles, thickness of the skin layers, skin lipid compo-
sition, and structure, could certainly affect the NP percuta-
neous penetration (Labouta and Schneider 2013). Another 
problem encountered by using hairy animals is damage of 
the skin barrier due to hair clipping.
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Placenta in vitro models
Models for studying transplacental transport have long 
been based on the perfused isolated human placenta studied 
in ex vivo study designs. The perfused isolated human pla-
centa ex vivo model presents a directly relevant alternative 
that maintains the complexity of the intact placenta (Saun-
ders 2009). Transport studies in the ex vivo intact placenta 
are technically challenging and require large quantities of 
substances to be tested. Therefore, models using repre-
sentative placental cell lines in Transwell study designs are 
being developed as in vitro alternatives. Most commonly 
used human placental cell lines are the BeWo, Jar, and 
JEG-3 cell lines, which have been applied to study trans-
placental transfer of a variety of drugs and compounds. 
The most popular cellular model consists of the BeWo cell 
line, representing a choriocarcinoma-derived placental cell 
line that strongly resembles cytotrophoblastic cells. The 
BeWo b30 subclone can be grown on Transwell inserts 
to form confluent cell layers, enabling the quantification 
of both uptake into the cells from the apical compartment 
(maternal side) and efflux from the cells to the basolateral 
compartment (foetal side) (Buerki-Thurnherr et al. 2012). 
In some studies these models have been validated by com-
parison of the transport rate across the Transwell cellular 
BeWo b30 layer and the transport rates detected in ex vivo 
placental models for the same compounds (Li et al. 2013; 
Poulsen et al. 2009).
Although the type and nature of the nanoparticles stud-
ied in in vitro placental models are different and the num-
ber of studies is limited, some general observations can be 
made. Nanoparticles can be transported across the placental 
barrier, where their size and type of nanoparticles influence 
the efficiency of the transport. Furthermore, in contrast to 
drugs and other xenobiotic bulk chemicals, transport of 
several nanoparticles across the placental barrier appears 
to be highly variable. The latter conclusion can be derived 
from the observation that for the nanoparticles studied so 
far the amount (%) of the nanoparticles transported across 
the BeWo b30 cell layer varies from 0.6 to 29 % in 6 h 
(Table 1). Comparison of this transport rate to that reported 
in the BeWo model for several chemicals mounting up 
to 30 % in 2 h reveals that the transport of nanoparticles 
across the BeWo cell layer, just as that of chemicals, may 
be limited or significantly depending on the type of nan-
oparticles. This implies that a validated in vitro model to 
quantify the potential transport of nanoparticles across the 
placental barrier would be of high value to set priorities for 
further in vivo testing, thereby avoiding in vivo testing of 
all newly developed nanoparticles.
General remarks on currently used in vitro models 
to study translocation of nanoparticles
Currently used in vitro models to study translocation of 
nanoparticles are mostly based on cell culturing on Tran-
swell inserts or on the use of ex vivo tissues. Transwell 
inserts can differ in the type of plastic they are made of and 
in the pore size of the permeable membrane. These differ-
ences between the Transwell inserts influence the trans-
location rate (Cartwright et al. 2012; Geys et al. 2006). 
Transwell inserts with a larger pore size give increased 
translocation rates compared with inserts with smaller 
pore sizes. In addition, some types of plastic of the Tran-
swell inserts yield decreased translocation due to nano-
particle adsorption on the material surface. Therefore, for 
each single type of nanoparticles, the translocation across 
the different types of inserts should be tested without cells 
to assess whether the nanoparticles are not withheld by the 
insert itself.
Next to this, different cell types are used, which clearly 
influences the translocation and the mechanism of trans-
location. When cell types lack the formation of tight junc-
tions, nanoparticles can easily pass between the cells result-
ing in a higher translocation rate compared with cell types 
that do form tight junctions. To prevent paracellular trans-
port, epithelial cells forming tight junctions are preferred. 
As already discussed, the incorporation of a mucus layer in 
gut epithelial models decreases the translocation (Walczak 
et al. 2014). This mucus layer might be a very important 
barrier for nanoparticles in vivo because of electrostatic 
repulsion (for negatively charged nanoparticles) and mucus 
entrapment (for positively charged nanoparticles) (Husain 
et al. 2001; Lai et al. 2007; Norris et al. 1998; Szentkuti 
and Lorenz 1995). Similarly, such a mucus layer might 
Fig. 4  In vitro diffusion chamber to test bioavailability of nanoparti-
cles across the skin barrier
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also be essential for in vitro lung barrier models, since 
nanoparticles first come in contact with the pulmonary sur-
factant if they are deposited in the lungs. Lastly, the use 
of specific cells types in co-culture on top of an epithelial 
layer can alter the translocation rate of the nanoparticles. 
For instance, alveolar macrophages in lung models can 
decrease the translocation rate by uptake of nanoparticles, 
while M cells in intestinal models can enhance transloca-
tion. The addition of these specific cell types can improve 
the in vitro models by more closely mimicking the in vivo 
situation in which, for example, the lungs are protected 
from particles via phagocytosis by alveolar macrophages.
Some reported in vitro models use primary cells, while 
others use immortalized cell lines. On one hand, primary 
cells have a more differentiated phenotype compared with 
cell lines. On the other hand, the isolation of primary cells 
is often experimentally challenging: the cells dedifferenti-
ate after isolation, differ from batch to batch, and prolif-
erate to a limited extent. Cell lines are easy to work with, 
well characterized and more homogenous, but they show 
only few characteristics of differentiated cells. Overall 
they only poorly represent the in vivo situation (Hartung 
et al. 2002; Klein et al. 2011). In in vitro lung transloca-
tion studies, primary rat alveolar cells have been frequently 
used (Fazlollahi et al. 2011; Geys et al. 2009; Yacobi et al. 
2008). Recent, biologically complex human intestinal tis-
sues have been cultured using human (induced) pluripo-
tent stem cells, resulting in human intestinal organoids that 
have secretory and absorptive functions (Brugmann and 
Wells 2013). Comparable systems have now been modified 
into mature epithelial, functional and polarized monolay-
ers grown on Transwell membranes, which are suitable for 
translocation studies (VanDussen et al. 2014).
Ex vivo models maintain the complexity of the physio-
logical barriers (Saunders 2009). However, transport studies 
in ex vivo models are technically challenging, time consum-
ing, and can require large amounts of the test substance.
Advances in the field of miniaturized and microfluidic 
devices have recently led to the concept of organ-on-a-chip 
models (Bhatia and Ingber 2014; Huh et al. 2012; Moraes 
et al. 2012; van der Meer and van den Berg 2012), which 
can be seen as hybrid devices combining cells and micro-
fabricated structures aiming to recapitulate the dynamic 
physical, cellular, and functional features of human tis-
sues (Ardavin et al. 2001; Huh et al. 2010. 2013; Schimek 
et al. 2013; Wagner et al. 2013). These devices first pro-
vide a high control on the cell microenvironment (e.g. 
physical and chemical parameters) together with dynamic 
culture conditions, since they are embedded in a microflu-
idic format (Whitesides 2006). Furthermore, these devices 
can include active elements, which allow exposing cells 
to mechanical stimuli and surface strains, by stretching 
the substrate on which they are grown (Sinha et al. 2015). 
These approaches mostly rely on 3D cell culture condi-
tions, which are acknowledged to better mimic the in vivo 
conditions compared with conventional monolayer models 
(Harink et al. 2013).
Over the years, examples of organ-on-a-chip models in 
the literature have diversified and, for instance, include gut 
(Kim and Ingber 2013), lung (Huh et al. 2007, 2010; Nalay-
anda et al. 2010), or even blood–brain barriers (Griep et al. 
2013; Huh et al. 2013; Wolff et al. 2015). These models can 
be of particular interest to the field of nanotoxicology. Huh 
et al., for instance, have developed a complex lung-on-a-
chip model, which recapitulates movements associated 
with breathing that is accompanied by cyclic stretching of 
cells (Huh et al. 2010). This device has been applied for NP 
testing, showing that breathing motion is essential for such 
nanotoxicological assays. The same group, using the same 
principle, later proposed a gut-on-a-chip model integrating 
peristaltic motion associated with digestion. Interestingly, 
exposed to a combination of dynamic culture and mechani-
cal strain, Caco-2 cells were producing mucus and micro-
villi features were formed (Kim and Ingber 2013). Finally, 
organ-on-a-chip devices are amenable to parallelization and 
automation; they are easily coupled to virtually any detec-
tion technique, and different organ models can even be 
combined on one device (Wagner et al. 2013) to eventually 
mimic the whole body/organism. The availability of such 
complex and in vivo-like models is expected to facilitate 
the implementation of the 3R’s legislation regarding animal 
experimentation (Marx et al. 2012; van de Stolpe and den 
Toonder 2013).
Accuracy of current in vitro translocation models 
compared to in vivo data
In vitro translocation studies show mostly limited transport 
of nanoparticles across the lungs, gut, skin, and placenta. 
In the sections below, we discuss the comparison between 
in vitro data and available in vivo data. We included in vivo 
studies that measured the bioavailability of similar nano-
particles compared to their in vitro counterparts. However, 
most in vivo data come from separate studies in which not 
exactly the same type of nanoparticle is used: for instance, 
the nanoparticles differ in size. Another marked difference 
is that the in vitro models are composed of cells (often cell 
lines) with a human origin, while the in vivo models mostly 
are rodents. Therefore, we first compared data from stud-
ies using nanoparticles of the same chemical composition 
although they sometimes differed for other characteristics. 
In Table 2, we included studies that used exactly the same 
nanoparticles in both an in vivo and an in vitro design.
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Lung barrier
The translocation rate between in vitro lung barrier mod-
els and in vivo inhalation studies differs depending on the 
tested nanoparticles (Table 2). In addition, some studies 
determined the cellular uptake and not the translocation 
rate of nanoparticles. The information on their localization 
can also be used in the comparison between in vitro and in 
vivo data.
For the most frequently used polystyrene nanoparticles, 
the translocation rate, both in vitro and in vivo, is very low 
1 day after exposure. Depending on the pore size of the 
inserts, the translocation amounts to 0–6 % in vitro against 
0.05–2 % in vivo. However, one in vivo study shows accu-
mulation over time of polystyrene nanoparticles in the thy-
mus (Sarlo et al. 2009), which cannot be demonstrated in 
an in vitro lung model. One in vitro study reported a size-
dependent translocation rate (Yacobi et al. 2008), which is 
in line with the size-dependent distribution shown after oro-
pharyngeal aspiration (Sarlo et al. 2009). Also for gold nan-
oparticles, the in vitro translocation rate ranges from 0.5 to 
5.2 % (Brandenberger et al. 2010). For comparison this can 
be compared to the in vivo translocation to the liver of 0.7 
to 2.8 %; clearly, this is an underrepresentation of the com-
plete systemic availability (Sadauskas et al. 2009; Sung et al. 
2011; Takenaka et al. 2006; Yu et al. 2007). For cerium diox-
ide, quantum dots, silica, and titanium dioxide nanoparticles, 
different translocation rates are found in vitro and in vivo. 
For cerium dioxide, the uptake rate in vivo is very low, and 
only about 10 % of the inhaled cerium dioxide was detected 
in the lungs (Geraets et al. 2012), while 80 % of the parti-
cles was internalized in cells in vitro (Raemy et al. 2011). 
After inhalation exposure, quantum dots could be detected 
in the liver and kidney at relatively high amounts of 15 and 
5 %, respectively (Ma-Hock et al. 2012). However, in vitro, 
no translocation of quantum dots across primary rat alveo-
lar epithelial cells was observed (Fazlollahi et al. 2011; Geys 
et al. 2009). Silica nanoparticles were able to translocate 
across monolayers of Calu-3, NCI-H292, and A549 cells 
in vitro (George et al. 2015), but were not detected in tra-
cheobronchial lymph nodes after inhalation exposure (Arts 
et al. 2007). However, the silica content was not measured in 
any other tissue or organ besides the lung and lymph nodes, 
so there might have been some in vivo translocation to the 
blood, liver, and other organs. Finally, titanium dioxide nan-
oparticles were internalized by A549 epithelial cells, mono-
cyte-derived macrophages, and monocyte-derived dendritic 
cells in vitro (Muller et al. 2010; Rothen-Rutishauser et al. 
2008), while the in vivo studies showed that most nanopar-
ticles retained in the alveolar space in the lung-lining fluid 
directly after exposure, and were found later mostly inside 
alveolar macrophages (Creutzenberg et al. 2012; Geiser et al. 
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The above-mentioned studies did not test exactly the 
same nanoparticles for the in vitro and in vivo set-ups. Arai 
et al. (2014) did test the same silver nanoparticles in vitro 
and in vivo. However, they did not measure the in vitro NP 
translocation but the presence of silver material in cells. 
They concluded that, in vivo, silver ions appear to trans-
locate from the lungs to other tissues rapidly. In vitro, Ag 
from AgNO3 binds to metallothioneins, whereas Ag nano-
particles accumulate in lysosomes (Arai et al. 2014). Multi-
walled carbon nanotubes (MWCNTs) were jointly tested in 
vitro and in vivo. However, this study focused on the devel-
opment of pulmonary fibrosis and did not measure tissue 
distribution or translocation. The results did show, however, 
that MWCNTs are taken up by alveolar macrophages both 
in vivo and in vitro (Taylor et al. 2014).
Intestinal barrier
Several in vivo oral studies have been performed, but only a 
very limited number of those in vivo studies can directly be 
compared to in vitro studies. Here, we focus only on stud-
ies that evaluated the uptake of food-relevant nanoparticles 
such as silica and titanium dioxide. In addition, studies that 
used model materials such as polystyrene are discussed, 
as polystyrene nanoparticles have also been used in vitro 
(Table 1).
Some studies investigated the in vitro and in vivo trans-
location of titanium dioxide across the gut epithelium. Six 
hours after a single oral administration of 130-nm TiO2, 
titanium could be detected in gut tissues, but due to the low 
concentrations, it could not be quantified (Brun et al. 2014). 
Janer et al. (2014) did not observe any increase in tissue 
concentration in vivo 24 h after a single dose of 100 mg/kg 
TiO2 of 18 nm, while very low translocation was observed 
in vitro (Janer et al. 2014). In another study, rats were 
exposed to 5 mg/kg of different types of TiO2 nanoparticles 
(mean particle size 40 nm, 40–50 nm, 120 nm and up to 
5 µm), and up to 96 h post-administration, no translocation 
of titanium was detected to blood, several organs and urine. 
Also, no translocation was observed in vitro (MacNicoll 
et al. 2015). In rats exposed for 30 days to 200 mg/kg body 
weight (bw) 75-nm TiO2 nanoparticles, no increased tita-
nium levels were detected in blood, liver kidney and spleen, 
while effects on liver and other organs have been reported 
(Wang et al. 2013). Titanium nanoparticles were also orally 
administered to rats, with a dose of 1 or 2 mg/kg TiO2 nan-
oparticles with a primary size of 20–60 nm (large agglom-
erates were present) for 5 days (Tassinari et al. 2014). Only 
a limited number of tissues were collected; interestingly, in 
spleen elevated Ti concentrations were found in the high 
dose group. Detailed analysis revealed the presence of 
130-nm (sp ICP-MS) or 200–400-nm (SEM-EDX) materi-
als in spleens (Tassinari et al. 2014).
Like titanium dioxide, silica is commonly used as 
food additives. Therefore, the oral uptake of silica nano-
particles was studied after 28 and 90 days of exposure to 
food-grade synthetic amorphous silica. Limited uptake 
was observed: only after 90-day exposure to 2500 mg/kg 
bw elevated Si levels were found in spleen (van der Zande 
et al. 2014). More studies are available that focussed on 
model polystyrene nanoparticles, and they generally high-
light the dependence of uptake and accumulation of poly-
styrene nanoparticles on several factors, including their 
size, surface charge, and type of coating material (Araujo 
et al. 2014; Hillery et al. 1994; Hillyer and Albrecht 2001; 
Hussain and Florence 1998; Hussain et al. 1997; Jani et al. 
1989). In general, smaller polystyrene nanoparticles were 
taken up across the GI tract to a higher extent than the 
larger ones (Jani et al. 1990); the non-ionic more than the 
carboxylated ones (Jani et al. 1989) and 407 poloxamer-
coated more than 188 poloxamer-coated nanoparticles 
(Hillery and Florence 1996; Hussain et al. 1997).
The estimated oral bioavailability of 50-nm polystyrene 
nanoparticles varied between studies from 0.2 to 1.7 % 
(Walczak et al., submitted) to 6.6 % (Jani et al. 1990). 
Strikingly, much higher bioavailability (23 %) was reported 
for 500-nm polystyrene nanoparticles (Hussain et al. 1997), 
while their 1-µm-size counterpart’s nanoparticles had a 
lower uptake (2 × 10−6 % detected in lymph fluid) (Seif-
ert et al. 1996). Also, the amounts of polystyrene nanopar-
ticles associated with intestinal tissues that were reported 
by Walczak (between 0.38 and 0.74 % depending on the 
type of polystyrene nanoparticles, calculated as a sum of 
the small- and large intestinal walls), were lower than the 
ones reported by others for 60-nm nanoparticles (between 
1.5 and 10 %, depending on the type (i.e. surface chemis-
try) of polystyrene nanoparticles used) (Hillery and Flor-
ence 1996; Hillery et al. 1994). Comparison of the oral in 
vivo bioavailability (0.2 and 1.7 %) (Walczak 2015), with 
the in vitro translocation values (1.6 to 12.3 %) of the same 
50-nm polystyrene nanoparticles (Walczak et al. 2014), 
shows lower uptake values in the in vivo model. Therefore, 
the in vitro model used by Walczak et al. appears to overes-
timate the in vivo translocation.
Skin barrier
In the literature, various in vitro assays (based on ex vivo 
skin tissue) have been used to determine percutaneous pen-
etration of nanoparticles. However, the scarcity of in vivo 
human data hampers proper evaluation of these models. 
The vast majority of in vitro studies focused on TiO2 and 
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ZnO nanoparticles found in sunscreens. Most, although 
not all in vitro studies find that these nanoparticles do not 
penetrate beyond the superficial layers of the stratum cor-
neum (Cross et al. 2007; Mavon et al. 2007; Wu et al. 2009; 
Zvyagin et al. 2008). One of the disadvantages of in vitro 
assays is that exposure duration is limited to 24 h, although 
long-term exposures would be closer to the real-life situa-
tion. Wu et al. (2009) compared in vitro and in vivo pen-
etration of nanoscale TiO2 (4 nm and 60 nm) in two ani-
mal models (hairless mice and pigs). After in vitro dermal 
exposure, TiO2 nanoparticles were not detected beyond the 
stratum corneum. However, in vivo, 30-day dermal expo-
sure to the same nanoparticles in hairless mice revealed, 
that in contrast to short-term in vitro exposure, TiO2 nano-
particles do reach viable skin layers (Wu et al. 2009). Fur-
thermore, after 60-day dermal exposure, TiO2 nanoparticles 
could penetrate through the skin, reach different tissues and 
induce diverse pathological lesions in several major organs 
(Wu et al. 2009). Deeper, although minimal, penetration 
into epidermal layers has also been found for ZnO nanopar-
ticles in an in vivo study in human volunteers (Leite-Silva 
et al. 2013). In a parallel in vitro–in vivo study, Monteiro-
Riviere et al. (2011) investigated the penetration of TiO2 
and ZnO nanoparticles in UVB-damaged porcine skin. 
Under both conditions, TiO2 and ZnO NP predominantly 
resided in the stratum corneum, although small amounts of 
TiO2 and ZnO were also detected in the viable skin layers. 
On the other side, not all in vivo studies report penetration 
of nanoparticles beyond the stratum corneum (Monteiro-
Riviere et al. 2011). For instance, Zvyagin et al. found in an 
in vivo study with human skin no penetration of ZnO (26–
30 nm) into the viable layers (Zvyagin et al. 2008). This is 
consistent with the findings reported by Mavon et al. show-
ing no penetration of TiO2 into the viable epidermal lay-
ers of human skin either in vivo or in vitro (Mavon et al. 
2007). Obviously, the discrepancy in the results cannot be 
explained solely by the differences between in vitro and in 
vivo data but also by the characteristics of the used nano-
particles (size, coating), exposure duration and sensitivity 
of the detection methods.
Another frequently investigated NP is silver, which is 
used on a large scale in medicinal and consumer products. 
Larese et al. found in an in vitro study with human skin that 
smaller silver nanoparticles (30 nm) can penetrate across 
the stratum corneum into the upper layers of the epidermis 
(Larese et al. 2009). This is consistent with in vivo data 
obtained in human volunteers (George et al. 2014) show-
ing that silver nanoparticles could penetrate as deep as the 
reticular dermis. Zhu et al. showed, using a highly sensitive 
detection method, that the penetration depth of Ag nano-
particles could exceed the stratum corneum thickness (Zhu 
et al. 2015).
Placental barrier
As described above, the transport efficiency of nanoparti-
cles across the human placenta is likely to be different from 
that in rodents (Wick et al. 2010). To study the transloca-
tion over the human placental barrier, dual recirculation 
human placental (ex vivo) perfusion models are used. In 
such a design the translocation of 50, 80-, 240-, or 500-nm 
polystyrene was studied, under highly controlled condi-
tions (i.e. translocation of a marker compound) (Wick et al. 
2010). After a single administration, 50-, 80-, and 240-nm 
polystyrene nanoparticles were observed in the foetal circu-
lation (foetal to maternal ratios 0.4; 0.4; 0.1, respectively), 
while the 500-nm polystyrene nanoparticles were retained 
in the placenta (Wick et al. 2010). In vitro similar results 
were found, where the translocation rate of 50-nm poly-
styrene nanoparticles was larger compared with 100-nm 
nanoparticles (Cartwright et al., 2012). Myllynen et al. per-
fused ex vivo human placentas with 10-, 15-, and 30-nm 
PEGylated gold nanoparticles (for up to 6 h) and did not 
observe any PEGylated gold nanoparticles in the foetal 
part of the placenta (Myllynen et al. 2008). In vitro, they 
observed internalization of PEGylated gold nanoparticles 
of 10 nm in BeWo cells up to 48 h after exposure (Myl-
lynen et al. 2008).
In rodents, fluorescent polystyrene nanoparticles were 
administered via the extraembryonic tissue. The embryos 
were ex vivo incubated for 12 h with 20-, 100-, and 500-
nm carboxylated and 200-nm amino-conjugated/termi-
nated polystyrene nanoparticles. The 20-nm carboxy-
lated nanoparticles were distributed in the embryonic and 
extraembryonic germ layers of ectoderm, mesoderm, and 
endoderm. The 100 and 500-nm carboxylated polystyrene 
nanoparticles accumulated in extraembryonic tissue. Inter-
estingly, the 200-nm amino-conjugated particles can pass 
into the embryos (Tian et al. 2009). For 5-nm gold nano-
particles, 0.018 % of the administered dose (118 µg/kg bw 
intravenous) administered to rats at day 19 of gestation was 
detectable in the embryo (Takahashi and Matsuoka 1981).
In addition, studies with silica nanoparticles showed 
that 70 nm, but not 300 or 1000 nm reached the brain and 
liver of the foetus after i.v. administration to the mother 
(Yamashita et al. 2011), while there was limited transport 
of 25-nm silica nanoparticles in vitro (Sonnegaard Poulsen 
et al. 2013). In the same study of Yamashita et al. 63-nm 
TiO2 nanoparticles were detected by TEM in brains and liv-
ers of foetuses (Yamashita et al. 2011). In another study, 
surface modified 28–30-nm iron oxide nanoparticles were 
administered (intraperitoneal) to mice from gestation days 
9–16. Nanoparticles with a positive zeta potential in water 
[coated with hydrophilic polyethyleneimine (PEI)] were 
detected in the livers of foetuses 1 day after dosing of the 
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dams, while negatively charged nanoparticles (coated with 
acrylic acid) could not be found in the foetuses (Di Bona 
et al. 2014). In vitro, iron oxide nanoparticles were able to 
cross a BeWo cell layer (Correia Carreira et al. 2013).
Based on these studies, it can be concluded that nano-
particles can pass the placenta of rodents and humans 
(ex vivo). This translocation is size- and surface charge-
dependent. Although there are few studies available to 
compare the in vitro translocation to the in vivo or ex vivo 
translocation, for polystyrene nanoparticles, size-dependent 
translocation has been observed both ex vivo and in vitro. 
However, for gold nanoparticles and iron oxide nanoparti-
cles the in vitro translocation was higher compared with the 
ex vivo or in vivo translocation, while for silica nanoparti-
cles it was lower.
Analytical techniques to quantify and characterize 
nanoparticle translocation in vitro and in vivo
Meaningful interpretation and comparison of the results 
obtained using different in vitro experiments and extrapola-
tion to in vivo data require reliable characterization of the 
nanoparticles and their aggregates, as well as matrix-based 
influences on the nanoparticles. Therefore, appropriate ana-
lytical techniques should be applied to determine the nano-
particle size distribution, composition, and concentration in 
the experimental samples.
Widely used methods to detect nanoparticles in liquid 
dispersions are dynamic light scattering (DLS), centrifu-
gal liquid sedimentation (CLS) (Braun et al. 2011; Cascio 
et al. 2015; Murdock et al. 2008; Nickel et al. 2014; Pow-
ers et al. 2006) and nanoparticle tracking analysis (NTA) 
(Filipe et al. 2010; Vasco et al. 2010). These methods allow 
determining an average size or size distribution related to 
the measured intensity signal. NTA is able to count and 
size nanoparticles in aqueous media at µg/L to mg/L con-
centrations (Filipe et al. 2010; Vasco et al. 2010). Both 
DLS and NTA are highly dependent on the polydispersity 
of the nanoparticle suspension and material properties 
of the particles since the scattered light of the individual 
particles must be sufficiently strong for detection. CLS is 
more robust since particles are size-separated before their 
actual detection and sizing. Transmission and scanning 
electron microscopy (TEM, SEM) are techniques to visu-
alize nanoparticles (Dudkiewicz et al. 2011; Zhang et al. 
2012). If pure nanoparticle dispersions are analysed, EM is 
currently the only technique that reliably covers the entire 
size range down to 1 nm. In cells or tissues, the minimal 
particle size that can be detected is around 20 nm, depend-
ing on the electron density of the nanoparticles (De Jong 
et al. 2010). Furthermore, EM distinguishes size aggregates 
and primary particles. Other imaging techniques are atomic 
force microscopy (AFM)(Brown et al. 2013) and particle-
induced X-ray emission (PIXE) spectroscopy (Lozano 
et al. 2012, 2013).
Elemental information about the sample can also be 
obtained by atomic spectrometry methods such as induc-
tively coupled plasma optical emission spectrometry 
(ICP-OES) (Elzey et al. 2012) and ICP mass spectrometry 
(ICP-MS) (Krystek 2012; Krystek et al. 2013), especially 
in single particle mode (sp ICP-MS) (Laborda et al. 2014; 
Pace et al. 2011; Peters et al. 2014a). From these studies it 
becomes clear that he smallest particle sizes that now can 
be determined are around 20 nm for silver and gold nano-
particles. For TiO2 and SiO2, nanoparticles size detection 
limits are around 50 and 200 nm; however, recent experi-
ments suggest that the size detection limit may become 
lower in the next few years. Another promising possibility 
is to combine size-specific techniques, that separate parti-
cles from each other, such as hydrodynamic chromatogra-
phy (HDC) or field-flow fractionation (FFF) with atomic 
spectroscopy techniques, that characterize particles, such as 
ICP-MS (Bednar et al. 2013; Hassellov et al. 2008; Peters 
et al. 2014b; Striegel and Brewer 2012; Von der Kammer 
et al. 2011). Currently, asymmetric flow field-flow fraction-
ation (AF4) is the most successfully used variant of FFF 
(Zattoni et al. 2014). In in vitro testing, AF4 coupled to 
ICP-MS becomes a powerful tool to investigate, for exam-
ple, time-dependent uptake of medium-sized silver nano-
particles (Krystek et al. 2015). Laser ablation (LA)-ICP-
MS has been used to quantify gold nanoparticles in single 
cells (Wang et al. 2014).
Most of the detection methods described above gener-
ally require sample preparation procedures. However, only 
little information concerning sample preparation techniques 
is available in the literature (Szakal et al. 2014). Aqueous 
media containing nanoparticles only need limited sample 
preparation; samples may be sonicated or tip-sonicated to 
suspend materials and proteins such as bovine serum albu-
min (BSA), or detergents such as sodium dodecylsulphate 
(SDS) may be added to stabilize nanoparticle suspensions 
(Jensen et al. 2011). For other matrices, matrix removal or 
nanoparticle isolation from the matrix can be achieved by 
physical processes such as centrifugation, filtration, column 
techniques or cloud point extraction, or by chemical or 
enzymatic destruction of the matrix (Loeschner et al. 2014; 
Peters et al. 2014a, b).
As mentioned not only size, but also, surface chemis-
try and charge, and composition of the so-called protein 
corona have been shown to significantly affect the translo-
cation of nanoparticles. The nanoparticle surface charge (or 
zeta potential) is routinely determined, but a correct inter-
pretation might be hampered by interactions of the matrix 
with these measurements. More details analysis of the sur-
face of the nanoparticles, for example, by matrix-assisted 
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laser desorption/ionization time-of-flight mass spectrom-
etry (MALDI-TOF) should be considered (Walczak et al. 
2014). Methods for the assessment of protein composition 
range from simple gel electrophoreses experiments to a full 
characterization of the biomolecules that are present using 
mass spectrometry-based techniques (Lesniak et al. 2010; 
Lundqvist et al. 2008; Tedja et al. 2012).
Overall, different techniques are available to determine 
the nanoparticle size distribution, composition and concen-
tration in experimental samples. Attention should be paid to 
the limits of the chosen techniques and to adequate sample 
preparation; this should be incorporated in studies report-
ing translocation data.
Conclusions on comparison of in vitro 
translocation models with in vivo data
While comparing the in vitro translocation to in vivo data, 
we noticed that very few studies tested exactly the same 
nanoparticles in in vitro and in in vivo settings. It seems 
that most studies are performed either in vitro or in vivo. 
Therefore, we focused our comparison on the nanoparti-
cle chemical composition although the nanoparticles stud-
ied sometimes differ in other particle characteristics such 
as size. Interestingly, this approach revealed that for some 
nanoparticles, the in vitro translocation is similar to the 
in vivo translocation. Examples are the translocation of 
polystyrene and gold nanoparticles in in vitro lung barrier 
models, and the translocation of titanium dioxide and silver 
nanoparticles in in vitro skin models. However, for other 
nanoparticles, major differences seem to exist between the 
in vitro translocation rate and the in vivo translocation.
These differences in translocation may be caused by the 
many differences existing between the in vitro barrier mod-
els and the in vivo study designs. First of all, the in vitro 
models mostly use an acute exposure of maximum 24 h 
and a short post-exposure time, while, for example, in vivo 
inhalation studies vary from 1 h to 13 weeks of inhalation 
exposure, 5 days a week, 6 h per day with post-exposure 
periods of up to 1 year. The relative short in vitro exposure 
durations might imply that only a fraction the nanoparticles 
that have been taken up (intracellularly) has been translo-
cated. Long-term exposures are not conceivable in an in 
vitro set-up, although this would be a more realistic expo-
sure scenario. Second, exposure concentrations between the 
in vitro and in vivo studies differ. In in vitro experiments, 
high particle concentrations are sometimes used to be able 
to detect the nanoparticles in the basolateral compartment. 
These high concentrations might increase the agglomera-
tion state of the nanoparticles and damage the epithelial 
barriers resulting in a different translocation mechanism 
compared with the in vivo situation. Clearly also in vivo 
dose selection can be critical, as it has been shown in rats 
that exposure to high concentrations to silica nanoparticles 
cause gelation (agglomeration) of silica nanoparticles in 
the gut (van der Zande et al. 2014). Third, in vitro mod-
els have a single basolateral compartment, while in vivo, 
nanoparticles can translocate to various tissues and organs. 
In the in vitro set-up, saturation might occur while under 
in vivo conditions nanoparticles can continue translocat-
ing, since they are taken up in organs and removed from the 
blood. On the other hand, this distribution of nanoparticles 
to various tissues can hamper translocation studies in vivo. 
Fourth, current in vitro models are almost all static, while 
in vivo exposure is dynamic. Fifth, nanoparticles adsorb 
proteins and/or phospholipids in biological fluids such as 
serum or lung-lining fluid (Landsiedel et al. 2014b). These 
proteins or phospholipids form a corona around the parti-
cles that affects their uptake and bioavailability (Lesniak 
et al. 2012). The proteins that are encountered in in vitro 
models, for example in foetal calf serum, are completely 
different from the proteins in vivo (i.e. rodent or human). 
Sixth, many in vitro lung models are submerged, which 
might alter the nanoparticle characteristics and thus the 
translocation rate, while most in vivo studies rely on inha-
lation exposure.
Conclusions
The aim of this review was to evaluate the performance of 
in vitro models that mimic different physiological barriers 
found in the human body by comparing—when possible—
the in vitro translocation of nanoparticles to their in vivo 
translocation across the lung, gut, skin, and placental barri-
ers. For all these barriers, a great variety of in vitro models 
are available to evaluate the translocation of nanoparticles, 
ranging in complexity from single-cell-type monolayer 
to multi-cell (3D) models. Many studies that use in vitro 
models on inserts focus on the toxicity of nanoparticles, do 
not include their translocation, and were thus not included 
in this review. Clearly, for a correct interpretation of the 
observed toxicity, the translocation (or systemic availabil-
ity, internal concentration) is a crucial parameter. In recent 
years, the availability of analytical detection methods to 
quantify and characterize the nanoparticles in in vitro set-
tings has improved considerably, which provides high-
quality data that are valuable in studying the relationship 
between physiochemical properties of the nanoparticles 
and their translocation. The improved analytical chemical 
detection methods also contributed to an increase in in vivo 
uptake data (bioavailability) of nanoparticles.
Here, while comparing the in vitro translocation to in 
vivo data, we noticed that very few studies tested exactly 
the same materials in both settings. Comparing data 
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obtained using nanoparticles of the same chemical compo-
sition, we found that for some nanoparticles, the in vitro 
translocation is similar to the in vivo bioavailability. Exam-
ples are the translocation of polystyrene and gold nanopar-
ticles in in vitro lung barrier models, and that of titanium 
dioxide and silver nanoparticles in in vitro skin models that 
are both in line with the in vivo data. However, for other 
nanoparticles, major differences were found between the 
in vitro and the in vivo translocation rate. As discussed in 
the sections above, many differences exist in the experi-
mental set-up between in vitro and in vivo study design 
that probably account for the poor correlation between 
these two types of studies. Especially, the changes in the 
physicochemical characteristics of the nanoparticles caused 
by the presence of lung-lining fluid, mucus, serum pro-
tein, and lipoproteins that form a corona should be taken 
into account, as these dramatically alter their recognition, 
uptake and translocation (Lesniak et al. 2012; Treuel et al. 
2013).
Risk assessment of nanoparticles (as is true for chemi-
cals in general) still heavily relies on in vivo studies using 
experimental animals. However, the latter must be reduced 
as far as possible, for numerous reasons. Therefore, there 
is an urgent need to validate existing in vitro models using 
data from animal models, although these animal models 
do not fully simulate the physiology of humans. How can 
we establish an in vitro barrier model that has value for the 
risk assessment of nanoparticles for humans? Ideally, in 
vitro models reflect the key mechanisms of corresponding 
in vivo end points, which cannot always be accomplished 
and may not be required if in vitro models reliably detect 
nanoparticles that are of concern in vivo (Landsiedel et al. 
2014b). The predictive value of in vitro models can be 
better assessed by testing exactly the same nanoparticles 
simultaneously in both in vitro and in vivo assays. If the 
ranking of the tested nanoparticles from the lowest trans-
location rate to the highest translocation rate is the same 
in both cases, the in vitro models provide information on 
the internal exposure, which is critical for the ultimate sys-
temic adverse effects. Then, the in vitro models can be con-
sidered as suitable for the risk assessment of nanoparticles 
and will in addition help to reduce animal testing by setting 
priorities for subsequent in vivo testing.
A crucial factor for both translocation studies is the sen-
sitivity of the analytical technique used for the quantifica-
tion of the translocation. While this is of importance also 
for in vivo studies, in vitro studies are more vulnerable for 
poorly performing methods. The observed low transloca-
tion rates combined with the relatively short exposure dura-
tions in vitro pose great analytical challenges. The absence 
of acute in vitro translocation should always be interpreted 
in relation to the sensitivity of the detection technique 
(both in terms of concentration and nanoparticle size). The 
introduction of in vitro models that allow chronic exposures 
are promising in that a chronic exposure better reflects the 
real-life human exposure.
In vitro models with a high predictive value do not nec-
essarily have to be complex, but can consist of a single cell 
type, as long as they give a similar ranking of nanoparticles 
as obtained in the in vivo situation. However, the mecha-
nism in these models might be completely different from 
the in vivo situation. To obtain more insight into the mech-
anisms behind nanoparticle uptake and translocation, in 
vitro models should be further developed to become physi-
ologically very close to the in vivo human conditions. Such 
in vitro models must be more complex because the human 
lung, gut, skin, and placental barrier consist of multiple cell 
types, which are exposed to a low concentration of nano-
particles. A physiologically realistic model will increase 
the confidence in the NP testing outcome, but it will also be 
elaborate and expensive to develop and maintain.
When in vitro models are available that either have a 
high human predictive value or are physiologically similar 
to the human situation, experimental data can be used to 
develop in silico models that will eventually be able to pre-
dict the human in vivo bioavailability of nanoparticles from 
their in vitro translocation rate. The (improved) in vitro 
models still needs validation, most likely using animal data, 
clearly alternative approaches need to be developed for this 
(making use of available human data).
We conclude that the current in vitro models to study the 
translocation of nanoparticles do not (yet) allow correlat-
ing to the reported in vivo translocation because of many 
differences between the in vitro and in vivo study designs. 
However, the use of in vitro models is very promising since 
they are currently further improved to mimic the in vivo 
situation more closely by, for example, using co-cultures 
of different cell types and implementing them in a micro-
fluidic format. When these models are further validated by 
testing exactly the same nanoparticles in an in vivo set-up 
as in the in vitro model, then, they can be used to determine 
the internal exposure (bioavailability) of nanoparticles and 
to set priorities for nanoparticles testing.
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